Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia

Collins, Molly; Ali, Shaheir; Wiss, Isabel Pupo; Senna, Maryanne M.

doi:10.1016/j.jaad.2022.05.023

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, its use may ultimately rely on a clinician’s judgment along with patient expectations and goals of care. While risk factors are always considered, HCQ is relatively well-tolerated among patients with a low incidence of adverse effects at appropriate doses [46, 79].…”

Section: Discussionmentioning

confidence: 99%

Use of Hydroxychloroquine in Hair Disorders

Ravipati,

Randolph,

Al-Salhi

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

Hydroxychloroquine (HCQ) is an antimalarial that is utilized to treat a range of dermatologic and autoimmune disorders. With its ability to alter immunologic mechanisms, it has been used to slow or halt the progression of hair loss in conditions secondary to autoimmune dysfunction. Lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and alopecia areata (AA) are hair disorders with underlying autoimmune components and no standardized treatment guidelines. We summarized the available literature on the use of HCQ to treat LPP, FFA, and AA. For all three conditions, HCQ showed variable efficacy from halted hair loss to no improvement. While patients did show success with HCQ treatment, there were no clear treatment patterns. Regimens ranged from HCQ monotherapy to combination treatments with other agents like steroids. Overall, HCQ should certainly be considered by clinicians as a treatment option for patient suffering from these hair disorders. While there is no standardized treatment, incorporation of HCQ should take into consideration individual patient characteristics, clinical judgment, and risks of side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Hydroxychloroquine in Hair Disorders

Ravipati,

Randolph,

Al-Salhi

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

Reply to “Response to Collins et al.’s ‘Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia’”

Collins¹,

Ezemma²,

Devjani³

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Assessment of hydroxychloroquine use and QT interval duration in female patients with frontal fibrosing alopecia

et al. 2023

View full text Add to dashboard Cite

per additional indoor tanning session. 1 Thus, indoor tanners in recent years may be at higher risk for developing melanoma. Our findings corroborate those of a smaller study that found an unadjusted increase in the percentage of U.S. indoor tanners reporting ≥25 annual sessions from 2007 to 2018. 4 However, our analysis additionally examined for statistical significance in these differences in unadjusted and adjusted prevalences.It is uncertain why indoor tanners are tanning at comparatively higher frequencies. Inexpensive indoor tanning packages and memberships may incentivize frequent indoor tanning. 5 Alternatively, legislation preventing indoor tanning for individuals under 18 years old, the Affordable Care Act's 10% indoor tanning tax, and other public health efforts may have disproportionately affected infrequent indoor tanners. 4 Research has suggested addictive properties of tanning. 4 The hardening hypothesis suggests tobacco control is the most successful among those less addicted to nicotine, which parallels our observations among indoor tanners. 4 We were limited to examination of population-level changes, rather than changes in individual behaviors, and were unable to examine more recent data due to a 2020 NHIS data quality issue. Future efforts should target high-frequency tanners given their tanning persistence and melanoma risk.

show abstract

Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia

Cited by 3 publications

References 4 publications

Use of Hydroxychloroquine in Hair Disorders

Use of Hydroxychloroquine in Hair Disorders

Reply to “Response to Collins et al.’s ‘Retrospective review of adverse events associated with oral hydroxychloroquine use in patients with cicatricial alopecia’”

Assessment of hydroxychloroquine use and QT interval duration in female patients with frontal fibrosing alopecia

Contact Info

Product

Resources

About